Transgene Biotek's Q1 FY 2026-27 Quarterly Results

Result Summary

• Transgene Biotek Ltd reported a 70.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 20.0%.
• Its expenses for the quarter were down by 31.8% QoQ and 8.2% YoY.
• The net profit decreased 15.2% QoQ and decreased 9.3% YoY.
• The earnings per share (EPS) of Transgene Biotek Ltd declined at 0.05 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Transgene Biotek Ltd is a company involved primarily in the biotechnology sector. The company focuses on the development of pharmaceutical products, aiming to address various medical needs through innovative solutions. As of the most recent update, specific details about major developments or new product launches by Transgene Biotek Ltd are not available. The company operates within an industry characterized by high research and development costs, lengthy product development cycles, and stringent regulatory requirements, which can significantly impact financial performance metrics.

Revenue

For the first quarter of fiscal year 2027 (Q1FY27), Transgene Biotek Ltd reported a total income of ₹0.06 crores. This represents a significant decrease of 70.0% compared to the previous quarter (Q4FY26) where the total income was ₹0.20 crores. However, when comparing year-over-year (YoY), there is an increase of 20.0% from Q1FY26, where the total income was ₹0.05 crores. These figures reflect the company's revenue-generating activities over the specified periods, showing fluctuations that may be typical in industries reliant on research and development.

Profitability

Profitability for Transgene Biotek Ltd in Q1FY27 shows a profit before tax of -₹0.39 crores, improving by 15.2% from -₹0.46 crores in Q4FY26. This is also an improvement from -₹0.43 crores reported in Q1FY26, marking a 9.3% YoY improvement. Profit after tax remains consistent with the profit before tax figures due to zero tax charges, indicating that financial outcomes are directly reflective of operational performance. The earnings per share (EPS) is -₹0.05 for Q1FY27, improving by 16.7% from -₹0.06 in Q4FY26 and also on a YoY basis from the same figure in Q1FY26.

Operating Metrics

In the first quarter of fiscal year 2027, Transgene Biotek Ltd's total expenses were reported at ₹0.45 crores. This is a decrease of 31.8% from Q4FY26 where expenses totaled ₹0.66 crores, and an 8.2% decrease from ₹0.49 crores in Q1FY26. The reduction in expenses QoQ and YoY may have played a role in improving the company's profitability metrics. The data indicates that the company has managed its operational costs with some level of efficiency during this period. However, due to the lack of data on other financial ratios such as P/E ratio, debt-to-equity ratio, or liquidity ratios like the current ratio, a comprehensive picture of operational performance remains incomplete.